Although infections caused by the straminipilan pathogen Pythium insidiosum were described in 19th century, it has been only recently that its epidemiology, immunology, treatment and other important traits were extensively studied. These studies were of paramount importance to theorize about the ecological niche for this pathogen, its host-parasite relationships, the antigens used for diagnosis, and the management of the infection using immunotherapy. P. insidiosum triggers in the infected host a T helper 2 [Th2] subset with an inflammatory reaction composed mainly of eosinophils and mast cells. These cells degranulate around the hyphal elements of P. insidiosum where a Splendore-Hoeppli-like reaction develops. In horses this reaction is so intensive that firm concretions called 'kunkers' develop. These data indicated that this pathogen might have developed an evolutionary strategy to conceal important antigens from the host immune system. Immunotherapy, a treatment approach that relies on the injection of antigens of P. insidiosum from in vitro cultures, has been successfully used in humans and horses to manage this disease. A switch from a Th2 to Th1 response is postulated as the most likely explanation of the curative properties of this approach. This review provides details on the serological, immunological, and immunotherapeutic methodologies used to diagnose and treat the infections caused by this pathogen.
and granular dermatitis in Japan [4] . It is believed that the first published descriptions of pythiosis were those of Smith [6] and Drouin [7] in the late 1800s. In both of these reports the authors commented on the presence of mycelial elements in the lesions [1] . The first definitive evidence of Pythium being caused by a 'fungal' organism was presented in 1895 by Fish [8] when he described hyphae that had the characteristic histologic appearance of an unnamed phycomycete in tissue sections from Florida horses with 'leeches'. Also in the late 1800s, Theodore Smith [9] described a disease known locally as 'leeches' because the firm elongated masses within cutaneous/subcutaneous lesions on the lower legs were thought to be aquatic leeches that had invaded the tissues as the animal stood in water. In 1901, de Haan and Hoogkaner [10] published extensive descriptions of several cases of what is believed to be pythiosis in Indonesian horses and named the disease hyphomycosis destruens. They also reported the isolation of a 'fungal organism' from these lesions. In a subsequent publication in 1902, de Haan [11] renamed the disease hyphomycosis destruens equi. The organism was isolated a second time by Witkamp in 1924 [12] . In 1961, the organism was given the name Hyphomyces destruens by Bridges and Emmons [13] . They considered the organism to be a phycomycete, possibly in the Genus Mortierella , based on its tissue morphology, as well as its broad, branched, sparsely septate, nonsporulating mycelium in culture. The authors did not follow the established rules of naming a new organism as outlined in the International Code of Botanical Nomenclature and the name H. destruens was not accepted [1] . The conclusion of Bridges and Emmons that H. destruens should be considered a phycomycete, was reinforced by Japanese workers using isolates from horses with granular dermatitis [14, 15] .
In 1974, Austwick and Copland [16] observed that isolates of H. destruens isolated from horses in New Guinea produced biflagellated motile zoospores. They suggested that the organism was a phycomycete belonging to the Pythiaceae and that it could be included in the genus Pythium . In 1980, Ichitani and Amemiya [17] isolated an organism from a horse in Japan and suggested that the organism was Pythium gracile. Two publications in 1987 also placed the organism in the genus Pythium . In 1987, DeCock et al . [1] working with isolates from animals (including the Japanese isolate above) found the organism to be the same in all and proposed the binomial Pythium insidiosum . Shipton [18] , working with Australian equine isolates and also the Japanese isolate above, proposed the binomial Pythium destruens. Most publications concerning this disease since 1987 have referred to the organism as P. insidiosum .
Pythiosis in animals
The disease has been described in a variety of animals in countries throughout the world. Most published accounts of the disease have been from horses and dogs. In horses, the disease manifests as an ulcerative, proliferative, pyogranulomatous lesion most often involving skin and subcutaneous tissue of the legs and ventral body wall [19] (Fig. 1a) . The disease has also been reported in the equine lung [20] , bone [21] and intestine [22] . Systemic involvement in three horses has been described [23] . The organism causes infection in dogs, which include cutaneous/subcutaneous and gastrointestinal lesions [24, 25] . The gastrointestinal presentation is most common in the dog [26, 27] . Other reported cases have been described from domestic cats (nasal cavity/retrobulbar space, skin/subcutaneous tissues) [27 Á/29] , cattle (skin/subcutaneous) [30] , sheep (skin/subcutaneous, disseminated) [31] , a dromedary camel (skin, gastric) [32] and a Central American Jaguar (lung) [33] .
Pythiosis in humans
In 1985, the first cases of human pythiosis were reported from patients living in Thailand [34] . Other human cases were described over the next 15 years [35 Á/ 43] . Three forms of human pythiosis have been observed: (i) granulomatous and ulcerative lesions involving the skin and subcutaneous tissues of the limbs and face, including the periorbital area, (ii) Ophthalmic pythiosis causing keratitis, and (iii) systemic pythiosis with vascular involvement leading to vasculitis, thrombosis and aneurysms [37, 38, 42] . Risk factors that appear to be involved in human pythiosis include hemoglobinopathy (thalassemia) and occupations requiring work in aquatic habitats (rice-fields, etc.) [41] .
Evaluating the immune response in mammalian hosts with pythiosis
The first serological assays to diagnose pythiosis in equines were developed early in the 20th century [12] . They were immunodiffusion (ID, precipitin), complement fixation (CF) and a skin test. It was clearly demonstrated that horses with active infection developed a cell mediated hypersensitivity reaction and the production of specific antibodies against the purified antigens of P. insidiosum . However, due to the association of pythiosis with other skin diseases of horses at that time [5] , this early study soon was forgotten. Sixty years later, Miller and Campbell [44] working with Australian horses with pythiosis, developed three different antigens based on the data published by Witkamp in 1924 [12] . These authors indicated that their serological tools accurately diagnosed equine pythiosis.
The studies of Witkamp [12] and Miller and Campbell [44] suggested that during infection, P. insidiosum expressed antigens that triggered a humoral immune response in the infected equines. These findings were supported by hypersensitivity testing in the skin of infected horses. Although Witkamp [12] was the first investigator to use a skin test in horses with pythiosis, he did not mention the immunotherapeutic benefits of this strategy. Miller [45] using Pythium antigens similar to those used by Witkamp found that P. insidiosum immunogens possessed therapeutic properties when injected in infected equines, a finding later supported by other investigators searching for therapeutic alternatives for pythiosis in Costa Rican horses [48, 49] .
Miller and Campbell [44] tested three antigens; a trypsinized antigen for ID, a freeze-thawed antigen for CF, and a soluble, precipitated antigen for skin testing. In this initial experiment, the ID test detected 100% of the infected equines. All apparently healthy horses were negative in this test. The CF test detected only 82% and the skin test only 64% of the horses studied. They also reported that anti-P. insidiosum immunoglobulins could not be detected by the ID test in horses successfully treated for pythiosis by immunotherapy. The latter two assays (CF and skin test), however, reacted positively with sera from normal horses used as negative controls. This finding suggested that these equines had been exposed to P. insidiosum without the typical lesions observed during pythiosis. In this initial study these investigators found evidence of crossreaction between anti-P. insidiosum immunoglobulins and antigens of Basidiobolus haptosporus, a finding later corroborated by others [48, 49] . Mendoza et al . in 1986 [50] developed a more sensitive antigen for the ID test. This new antigen detected more precipitin bands in experimentally infected rabbits, as well as, in sera of infected horses. Although the ID test, using Mendoza et al . [50] soluble antigen, had been successfully used in humans, dogs and other species infected with P. insidiosum , it soon became clear that the ID test was not always useful in other mammals with the disease [51, 52] . This finding motivated the evaluation of more sensitive assays for pythiosis.
In 1987, Mendoza et al. [53] introduced a specific fluorescent-antibody assay that differentiated the hyphae of P. insidiosum from other filamentous fungi in the host's infected tissues. These authors adsorbed anti-P. insidiosum rabbit sera with the hyphal elements of P. declinum and P. graminicola, and developed a specific tool to detect the hyphae of P. insidiosum . A similar strategy was used one year later by Brown et al . [54] . They developed an indirect immuno-peroxidase assay that specifically detected P. insidiosum in tissue. Although they did not adsorb their reagent, no crossreaction was detected with this assay when tested with the hyphae of three different zygomycetes. These two assays have been contributions in the identification of the hyphae of P. insidiosum in tissue, especially when culture of the organism is not possible. Another test, immunoblot, was introduced in 1992 [48] . This immunological tool was initially developed to analyse the antigens of P. insidiosum detected by the IgG-humoral immune response during infection. However, this strategy has also been recently used as a specific diagnostic tool to diagnose pythiosis in different species [55 Á/58] . Owing to the insensitivity of the ID test and cross reactivity of the CF and skin test, an ELISA test was developed [55, 56] . Investigators have found ELISA to be specific and sensitive in detecting pythiosis in all infected hosts [43,57 Á/59] . These serological tests were of paramount importance in the characterization of the humoral response to P. insidiosum during infection, and as a diagnostic tool for the disease. These findings suggest that the anti-P. insidiosum humoral response is also stimulated in infected hosts with pythiosis. The finding, using an ELISA test, that serum IgE changed before and after Pythium immunotherapy is one example on how this test has increased our knowledge of the humoral response to P. insidiosum antigens in horses. More recently, Hutchens and Mendoza [60] introduced a simple latex agglutination test for the rapid diagnosis of pythiosis. This new test was more sensitive than the ID test, but specificity was low. The data so far collected from serological studies have been instrumental in explaining the cascade of immunological events trigger by the antigens of P. insidiosum in infected and vaccinated hosts (see below) [46] .
Pythium insidiosum host Á
/parasite relationship Pythium insidiosum cannot penetrate healthy skin. The studies of Ravishankar et al . [61] showed that the hyphal apices of this pathogen exerted forces of up to 6.9 mN when tested against different surfaces, including human and animal skin. However, this force is not strong enough to penetrate healthy skin. The study showed that this pathogen requires prior skin damage to invade its mammalian host. Once inside the host, P. insidiosum triggers an eosinophilic granulomatous reaction with giant cells, mast cells, macrophages, plasma cells, and a few lymphocytes [4, 19] . This reaction is similar to that observed in infections caused by the fungal pathogens Basidiobolus ranarum and Conidiobolus coronatus [5] and also to the reactions seen in many parasitic infections [5] . Because these two entomophthoraceous fungi and some parasitic infections mimic the clinical manifestations of the infections caused by P. insidiosum in both humans and animals, an accurate differentiation between these pathogens is essential for the proper diagnosis and treatment [4, 5] . Since the first report of pythiosis in horses it was evident that P. insidiosum , causes an eosinophilic reaction leading to the development of a SplendoreHoeppli like material around hyphae in tissues. In horses the reaction is so pronounced that the eosinophils heavily degranulate around the hyphae of P. insidiosum forming the firm concretions termed 'kunkers' [4, 19, 62] . 'Kunkers' have not been found in other species affected by this oomycetous pathogen [27, 28, 30, 31, 34, 35, 38] . The infection in humans and animals indicated that P. insidiosum triggers a prominent eosinophilic inflammatory reaction, as a response to antigens released by the hyphae invading the infected hosts [4, 27, 38] . It is interesting to note that the hyphal elements of P. insidiosum are usually found in the center of eosinophilic micro-abscesses. This feature has been used by some investigators to postulate that a Th2 subset is probably activated by the immunogens expressed by P. insidiosum in the infected hosts [46] .
The pathogenesis of the disease has been linked, in part, to the degranulation of eosinophils and mast cells around the hyphae of P. insidiosum , although other immunological mediators have also been incriminated [44, 46, 47] . It is believed that the degranulation of these inflammatory cells is largely responsible for the extensive tissue damage observed in humans and animals with pythiosis. Clinically, extensive ulceration of the skin accompanied by the production of large amounts of granulation and fibrous tissue are main characteristic of the cutaneous infections [4, 5, 19, 44] . In horses the lesions are so extensive that the disease has been termed 'swamp cancer' or 'summers sores'. Skin lesions in horses can reach 500 cm in diameter [63] . When P. insidiosum invades internal organs the development of tumor-like masses, often misdiagnosed as neoplasms, is the main feature [4, 5, 27, 28, 30] . Further evidence that a Th2 response has been triggered by P. insidiosum immunogens, and thus presented to local dendritic cells, came from the studies of Wachiwanawin et al . [41] . These authors reported that in humans with arterial pythiosis, interleukin-4 (IL-4) and IL-5 were elevated. The subsequent finding of elevated IgE levels in humans and horses with the disease strongly validated the concept of a Th2 modulation by this pathogen during natural infection.
Under this scenario, the hyphae of P. insidiosum express a soluble exoantigen that modulates the host's immune response to a Th2 subset. The expression of such antigen released outside the cytoplasmic compartment, was first recorded in 1987 [53] . These investigators reported that when some 'kunkers', embedded in infected equine tissues, were investigated with fluorescent antibodies, the whole 'kunker' fluoresced. This finding suggested that an antigen, detected by the labeled anti-P. insidiosum immunoglobulin, had been released from the hyphae. Apparently, some of the antigen is retained in the 'kunkers', from where it is released to the surrounding tissues and then presented to local dendritic cells. It has been suggested that this soluble antigen may be responsible, not only for the immune modulations to a Th2 subset, but it also might play a key role on locking the immune system into a Th2 subset. This hypothesis also suggests that the exoantigens released by P. insidiosum may play an important role in the development of pathological changes observed during pythiosis [46] . We believe that the host's immune system gets deceived by P. insidiosum exoantigens. Because the host immune system is always detecting the antigens that this pathogen presents to the local dendritic cells, the host is always producing more eosinophils and mast cells. Furthermore, the pathogen uses the host's defenses to camouflage itself inside the eosinophilic material formed by the eosinophil degranulation. This evolutionary strategy could protect the pathogen from being fully presented to the host's immune system [45 Á/47] , thus reassuring its presence in the infected tissues. Based on the destructive effect of the inflammatory response triggered by this pathogen on the infected hosts, and the fact that it is the only mammalian oomycete pathogen, it could be speculated that P. insidiosum only recently developed the ability to survive in mammalian tissues, a belief also supported by current phylogenetic analysis [64] .
An animal model to evaluate the immune response triggered by Pythium insidiosum and its antigenic therapeutic features It is well known that the species frequently diagnosed with pythiosis are resistant to experimental infection by P. insidiosum [4] . In fact, the only susceptible animal model for experimental pythiosis, is the rabbit [12, 65, 66] . This is very unusual since natural pythiosis in rabbits has yet to be reported. The first investigator that successfully reproduced pythiosis in rabbits was Witkamp [12] . He induced eosinophilic granulomas in the rabbits after intraperitoneal or intravenously injections of the P. insidiosum hyphae isolated from horses with cutaneous pythiosis found in India. He reported the same results after placing 'kunkers', recovered from the infected horses, in the rabbit's tissues. He reported that the sera from experimentally infected rabbits reacted positively when tested in a CF test. Amemiya in 1969 and 1982 [15, 65] reported the successful reproduction of pythiosis in rabbits using hyphae of P. insidiosum isolated from Japanese horses. This investigator stated that he was able to reproduce cutaneous, intestinal, arterial, and systemic pythiosis in experimental rabbits. In the 1982 report, he illustrated his finding with beautiful color plates showing microscopic and macroscopic details of his experiments. One year later Miller and Campbell [66] were the first investigators to incriminate in vitro developed zoospores, as the putative infecting units of this oomycete pathogen. These investigators used zoospores from P. insidiosum to reproduce the infection in healthy and cortisone-treated rabbits. Their data showed that both groups of rabbits were equally infected by these zoospores, suggesting that P. insidiosum could cause infection even in immunocompetent rabbits. PatinoMeza [67] in an effort to reproduce pythiosis in susceptible species using zoospores was unsuccessful in causing disease when zoospores were injected into horses and dogs. However, he was able to induce pythiosis when injected into rabbits. Data collected in these studies suggested that the zoospores, and other propagules of P. insidiosum , might require unknown elements to initiate pythiosis in the contacted mammalian hosts.
Since then other investigators have used rabbits to study the cell mediated response induced by P. insidiosum and for the production of immunoglobulins to evaluate and develop diagnostic tools [49, 50, 54, 59, 68, 69] . Santurio et al . [59] used rabbits to evaluate three different formulations used for immunotherapy. After first inducing pythiosis he injected the sick rabbits with three immunotherapeutic antigens derived from P. insidiosum . Using this strategy, they not only evaluated these three immunogens, but their results suggested that the response to immunotherapy could be easily monitored using the rabbit model. More recently, rabbits have been used to evaluate the immune-prophylactic potential of a variety of P. insidiosum immunogens (B. Glass, personal communication).
The use of immunotherapy to treat pythiosis in humans and animals
Pythium insidiosum is resistant to most antifungal drugs [4] . One explanation for this could be the fact that this oomycete lacks ergosterol in its cytoplasmic membrane. Because of this, surgery and other less traditional drugs and methods have been used for the treatment of this disease, often with less than satisfactory results [4, 5, 27, 36, 38] . One of the new treatments has been the use of P. insidiosum -derived antigens in immunotherapy against pythiosis.
As previously mentioned, Witkamp [12] first used a skin test to evaluate the cellular immunity in horses. However, he did not mention if a cure was achieved after this experiment. Miller [46] was the first investigator to report that the culture-derived antigens of P. insidiosum possessed therapeutic properties when injected into horses. The same year another group described a similar finding in Costa Rican horses [63] . While using culture-derived Pythium immunogens in skin tests to investigate the epidemiology of equine pythiosis these two groups independently found that the injected immunogens of this oomycetous pathogen resulted in the cure of Â/50% of the treated animals. Miller et al . [70] in a later report questioned the effectiveness of this new immunological treatment (immunotherapy) when some of the horses injected failed to improve. Other investigators reported that P. insidiosum immunogens were not 100% effective in chronic cases [47] . Later work using the same antigens as Miller [45] , and those used by Mendoza et al . [63] , showed that 100% of early cases of the disease ( B/20 day old lesions) were cured, whereas only 20Á/40% of the chronic cases responded to immunotherapy (!/2 months old lesions). Since then, immunotherapy has been successfully used in more than 500 hundred equine cases of pythiosis [46] . Using a new immunotherapeutic formulation, Mendoza et al . [46] reported 60% of effectiveness in horses subjected to immunotherapy alone (Fig. 1, Table 1 ). The combination of surgical debridement of diseased tissue followed by immunotherapy increased the cure rate to approximately 90% when tested on several cases of chronic cutaneous pythiosis in horses. In addition, immunotherapy has recently been successful in cattle with pythiosis. However, no published data are available. In cattle, the effectiveness of immunotherapy on disease cure rate approached 100% (R. C. Pérez, personal communication).
In contrast to the results obtained in horses and cattle, immunotherapy in cats and dogs has been disappointing. Only 33% of the treated dogs and none of the five cats treated to date responded successfully to immunotherapy [27, 46, 71] (Table 1 ). The cause of this failure is unknown but one explanation might be that most dogs and cats with pythiosis are diagnosed several months after the initial onset of infection resulting in animals with weakened immune systems that poorly respond to immunotherapy. The two classical clinical forms (skin and gastrointestinal) of the disease in dogs mimic several cutaneous and intestinal diseases [25,27Á/29] , thus complicating the differential diagnosis. The failure of an accurate clinical diagnosis and the fact that most clinicians are unfamiliar with the disease, may explain why most cases are initially misdiagnosed as cutaneous bacterial or fungal infections or as intestinal neoplasms such as lymphoma [27] .
In addition to horses, dogs and cattle immunotherapy has been successfully tested in human patients in Thailand suffering with arterial pythiosis [39, 41] . This type of pythiosis in humans has had a 100% mortality rate. In the first case of immunotherapy for pythiosis, a young boy with terminal pythiosis in his carotid artery was successfully treated with Pythium immunotherapy [39] . He had failed to respond to antifungal therapy and was treated with immunotherapy on an experimental basis. The dramatic recovery of this boy after immunotherapy was surprising. The boy reacted with a mild inflammatory response at the site of injection that subsided two days post treatment. No deleterious side effects were reported after two injections with P. insidiosum immunogens. This first human case cured by immunotherapy suggested that this treatment approach might be an effective and safe method of treatment of human arterial pythiosis. Recently, Wachiwanawin et al . [41] using a new formulation described previously in horses, dogs, and a human, found that this approach successfully cured four of eight Thai cases of terminal arterial pythiosis (Table 1 ). This study indicates that immunotherapy should be considered in cases of cutaneous and arterial pythiosis in humans. Although immunotherapy has yet to be tested in the cutaneous form, these data indicate that it is a safe approach for any clinical form of pythiosis in humans.
Data collected in the US using P. insidiosumimmunotherapy as a curative option for animals, was approved by USDA as an experimental option for diseases with or without chemotherapeutic substitutes. In Thailand most physicians used this curative approach as a last resort in cases of human arterial pythiosis. As mentioned earlier, only rabbits are susceptible to experimental pythiosis. Thus, the majority of information on immunotherapy has been collected from naturally infected treated hosts. Although, this could initially appear as a disadvantage, it could be more powerful than data collected in an animal model. Accordingly, data collected from clinical trials in the past 10 years indicated that: (i) that immunotherapy is safe, in both human and animals, (ii) it cures Â/60% of treated hosts, and (iii) it appears to modulate the host immune response in treated recipients. Data collected in the last two decades suggest that this new concept The immunotherapeutic agent used in each of the injected hosts was a mixture of high molecular weight exo-and endoplasmic antigens of Pythium insidiosum [41, 46] . §, Rosa Cristina Pérez, personal communication; ', Unpublished data; *, Unpublished data; $, [39, 41] . could be extrapolated to chronic subcutaneous mycoses and, in principle, to deep mycoses as well.
Hypothesis behind the curative properties of Pythium insidiosum antigens used for immunotherapy
Immunotherapeutic approaches to infectious disease treatment using microbe-derived antigens have been previously investigated [72 Á/74] . However, the immunogens derived from P. insidiosum have been more successful than any of the immunotherapeutic antigens investigated to date in other chronic diseases [39,41,47,59,70 Á/76] . Early reports indicated that a mixture of in vitro derived P. insidiosum immunogens triggered an immune response that seemed to kill P. insidiosum [41, 46] . These reports suggested that the injected immunogens displayed to the host's immune system, antigens that were not properly presented during natural infection to stimulate a protective response. They stated that the development of a mononuclear response and the disappearance of the eosinophilic reaction around the hyphae, after successful immunotherapy, were findings consistent with this idea. Similar observations have been published by Santurio et al . [59] and Monteiro [77] using immunotherapy in horses with pythiosis in Brazil. Thitithanyanont et al . [39] , after successfully curing a young boy from Thailand with arterial pythiosis using culture-derived antigens of P. insidiosum , speculated that a switch from a Th2 to a Th1 response was the most likely trigger behind the curative properties of this immunotherapeutic approach. This hypothesis was based on the fact that the Th2 subset produces IL-5 and IL-4, as well as, IgE, IgG, and IgM precipiting immunoglobulins, all factors involved in the initiation of hypersensitivity and eosinophilia. In contrast, the Th1 subset produces IL-2 and IFN-g and it is involved in cytotoxic T lymphocytes [CTL] expansion, macrophage activation, and IgG isotypes mediating complement activation on sensitized pathogens. These authors, and more recently others [46, 71, 78, 79] , have indicated that the disappearance of the eosinophilic response and the expression of a mononuclear reaction after Fig. 2 The working hypothesis on the immunotherapeutic mechanisms triggered by Pythium insidiosum antigens. The left side of the chart shows the events during natural infection. It is believed that exoantigens of P. insidiosum (large circles around the hyphae) are processed by antigen presenting cells (APC) and then fully present them to naïve T helper cells (Th0). The Th0 cells differentiate into a T helper 2 (Th2) subset expressing large quantities of IL-5, IL-4, and other Th2 related cytokines. The IL-4 may stimulate B cells to produce IgE and also precipitin IgG and IgM (detected in most serological assays). In turn, IL-5 and IgE stimulate mast cells and eosinophils to migrate to the infection site. These inflammatory cells degranulate around the hyphae (Splendore-Hoeppli phenomenon) causing tissue damage, and in the process masking the hyphae of P. insidiosum from the host's immune system. IL-4 could also down-regulate the Th1 response further locking the host's response into a Th2 subset (round dotted arrow). After immunotherapy (left side of the chart), the in vitro derived antigens of P. insidiosum are processed by local APC in a different fashion than during natural infection. After presentation, the Th0 cells developed into a Th1 subset expressing large quantities of interferon gamma (IFNg) and IL-2 that trigger a mononuclear cell-mediated immune (CMI) response including putative cytotoxic lymphocytes (CTL) and macrophages. It is believed that the cellular immunity is directly responsible for the killing of P. insidiosum hyphae. B cells are also stimulated to produce putative IgG for long-term protection. The continuous production of IFNg down-regulates the Th2 response breaking the cycle created by the exoantigens during natural infection (rectangular dotted arrow). Adapted from Mendoza et al . [46] . [41] , suggested that the in vitro derived immunogens of P. insidiosum might be presented to the local dendritic cells in a different fashion than during natural infection, thus stimulating a Th1 rather than Th2 response. They also noted higher titers of IL-4 and IL-5, and IgE previous to immunotherapy in a human with arterial pythiosis, and a decrease of these cytokines together with an increase of IL-2, after successful immunotherapy. This finding and those published by others [39,45Á/ 47,59,71,79] strongly suggests that a down regulation of a Th2 subset coupled with an up regulation of a Th1 response had occurred. Mendoza et al . [46] also reported low titer of IgE in cured horses after immunotherapy. These investigators found, on histopathological studies of the infected tissue before and after immunotherapy, that upon injection, a mononuclear reaction is triggered and that the hyphal elements of P. insidiosum are apparently destroyed by these mononuclear inflammatory cells. The damaged hyphal elements were observed as empty tubular structures, only identified as P. insidiosum hyphae by specific immunofluorescence staining [46] .
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Based on these developments [39, 41, 46, 47, 77, 78] , Mendoza et al . [46] recently proposed a hypothesis to explain the mechanisms behind the immunotherapeutic properties of these antigens. A summary of this proposal is shown in Fig. 2 . This hypothesis predicts that the development of a CMI response and the down regulation of the Th2 subset might be responsible for the curative properties of the immunogens used for immunotherapy.
Future directions
Although most of the immunological studies have been conducted to evaluate crude extracts of P. insidiosum in serological assays, the identity of these antigens remains to be determined. For instance, numerous investigators have reported several immunodominant antigens since 1992 [48,50 Á/52,59] . However, studies to investigate their identity and function at the molecular level has not yet been possible. Their identification is a logical next step. It is likely that the cloning and sequencing of these important antigens will take place in the near future, which will allow for better characterization of the immunogens. The use of these immunogens in the rabbit model should lead to a more detailed and complete picture of the immunopathology and lesion genesis of pythiosis and also give us a better understanding of the immunology involved in successful treatment (or treatment failure) following immunotherapy.
A new understanding of P. insidiosum and the disease that it causes should be possible over the next 20 years using modern techniques of immunology and molecular biology. Additionally, a developing awareness in veterinary and human medicine for pythiosis and the development of better diagnostic tests for pythiosis should make early diagnosis of the disease a much more common event. Early diagnosis of the disease and the development and use of improved immunotherapeutic preparations for pythiosis should lead to a better prognosis to this devastating disease of animals and humans.
